Jump to content

Tesetaxel

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by OrganoMetallurgy (talk | contribs) at 14:58, 14 June 2017 (added Category:Tert-butyl compounds using HotCat). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Tesetaxel
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • (2aS,2bR,3S,4S,6S,8aR,10S,11aS,11bR,13aR)-2a-(acetyloxy)-6-{[(2R,3S)-3-[(tert-butoxycarbonyl)amino]-3-(3-fluoropyridin-2-yl)-2-hydroxypropanoyl]oxy}-10-[(dimethylamino)methyl]-4-hydroxy-7,11b,14,14-tetramethyl-2a,2b,3,4,5,6,8a,11a,11b,12,13,13a-dodecahydro-2H-4,8-methano[1,3]dioxolo[3,4]cyclodeca[1,2-d][1]benzoxet-3-yl benzoate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC46H60FN3O13
Molar mass881.98 g/mol g·mol−1
3D model (JSmol)
  • CC1=C2[C@@H]3[C@H]([C@@]4(CC[C@@H]5[C@]([C@H]4[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C6=C(C=CC=N6)F)NC(=O)OC(C)(C)C)O)O)OC(=O)C7=CC=CC=C7)(CO5)OC(=O)C)C)O[C@@H](O3)CN(C)C
  • InChI=1S/C46H60FN3O13/c1-24-28(58-40(54)34(52)33(32-27(47)17-14-20-48-32)49-41(55)63-42(3,4)5)21-46(56)38(61-39(53)26-15-12-11-13-16-26)36-44(8,19-18-29-45(36,23-57-29)62-25(2)51)37-35(31(24)43(46,6)7)59-30(60-37)22-50(9)10/h11-17,20,28-30,33-38,52,56H,18-19,21-23H2,1-10H3,(H,49,55)/t28-,29+,30+,33-,34+,35+,36-,37+,38-,44+,45-,46+/m0/s1 ☒N
  • Key:MODVSQKJJIBWPZ-VLLPJHQWSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Tesetaxel (DJ-927) is a drug being investigated for chemotherapy of various types of cancer, including breast cancer,[1] gastric cancer,[2] and other solid tumours.[3]

References

  1. ^ Clinical trial number NCT01609127 for "Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer" at ClinicalTrials.gov
  2. ^ Clinical trial number NCT01348009 for "Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer" at ClinicalTrials.gov
  3. ^ Saif, M. W.; Sarantopoulos, J.; Patnaik, A.; Tolcher, A. W.; Takimoto, C.; Beeram, M. (2011). "Tesetaxel, a new oral taxane, in combination with capecitabine: A phase I, dose-escalation study in patients with advanced solid tumors". Cancer Chemotherapy and Pharmacology. 68 (6): 1565–1573. doi:10.1007/s00280-011-1639-3. PMID 21547572.


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tesetaxel&oldid=785623827"